X
[{"orgOrder":0,"company":"HengRui","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates Phase II\/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"HengRui","sponsor":"Hutchmed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Initiates Phase II\/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by HengRui
Filters
Companies By Therapeutic Area
Details:
Hutchmed will initiate a clinical advancement of their lead product Sulanda (surufatinib) in combination with camrelizumab for the treatment of naïve pancreatic ductal adenocarcinoma.
Lead Product(s):
Surufatinib ,Camrelizumab
Therapeutic Area: Oncology
Product Name: Sulanda
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Recipient:
Hutchmed
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
May 15, 2024
Details:
Fruzaqla (fruquintinib) is a selective oral VEGFR inhibitor, playing a pivotal role in blocking tumor angiogenesis. It is being investigated in combination with sintilimab for endometrial cancer.
Lead Product(s):
Fruquintinib ,Sintilimab
Therapeutic Area: Oncology
Product Name: Fruzaqla
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Recipient:
Hutchmed
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 13, 2024